Need for Standardization of Cytokine Profiling in CAR T-Cell Therapy

Authors

D Nathan Biery, Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD;; George Washington University School of Medicine, Washington DC.
David P. Turicek, Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD;; Division of Biology and Biomedical Sciences, Washington University, St. Louis, MO.
Caroline Diorio, Division of Oncology, Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, PA.
Brett A. Schroeder, Department of Hematology and Medical Oncology, CCR, NCI, NIH, Bethesda, MD.
Nirali N. Shah, Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD;. Electronic address: nirali.shah@nih.gov.

Document Type

Journal Article

Publication Date

3-25-2024

Journal

Molecular therapy : the journal of the American Society of Gene Therapy

DOI

10.1016/j.ymthe.2024.03.030

Abstract

With expansion of CAR T-cell therapy and broader utilization of anti-cytokine directed therapeutics for toxicity mitigation, the routine assessment of cytokines may enhance understanding of toxicity profiles, guide therapeutic interventions, and facilitate cross-trial comparisons. As specific cytokine elevations can correlate with and provide insights into CAR T-cell toxicity, mitigation strategies, and response, we explored the reporting of cytokine detection methods and assessed for the correlation of cytokines to CRS and ICANS across clinical trials. In this analysis we reviewed 21 clinical trials across 60 manuscripts that featured a Food and Drug Administration-approved CAR T-cell construct or one of its predecessors. We highlight substantial variability and limited reporting of cytokine measurement platforms and panels used across CAR T-cell clinical trials. Specifically, across 60 publications, 28 (46.7%) did not report any cytokine data, representing 6 of 21 (28.6%) clinical trials. In the 15 trials reporting cytokine data, at least 4 different platforms were used. Furthermore, correlation of cytokines with ICANS, CRS, and CRS severity was limited. Considering the fundamental role of cytokines in CAR T-cell toxicity our manuscript supports the need to establish standardization of cytokine measurements as a key biomarker essential to improving outcomes of CAR T-cell therapy.

APA Citation

Biery, D Nathan; Turicek, David P.; Diorio, Caroline; Schroeder, Brett A.; and Shah, Nirali N., "Need for Standardization of Cytokine Profiling in CAR T-Cell Therapy" (2024). GW Authored Works. Paper 4483.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4483

Department

School of Medicine and Health Sciences Student Works